Yaldır Emel, Cengiz Balça Begüm, Mülkem Osman Furkan, Bilgin Muzaffer, Açıkalın Mustafa Fuat
Faculty of Medicine, Department of Pathology, Eskişehir Osmangazi University, Eskişehir, Turkey.
Department of Pathology, Kütahya Health Sciences University Evliya Çelebi Education and Research Hospital, Kütahya, Turkey.
J Endocrinol Invest. 2025 May 30. doi: 10.1007/s40618-025-02610-8.
There are currently no definitive prognostic markers that accurately predict malignant behavior in pheochromocytoma/paraganglioma (PCC/PGL). While metastasis develops in only 10-15% of adrenal-origin, this rate can rise up to 50% in those with extra-adrenal localization. This study aims to investigate the potential predictive effect of known histopathological features in PCC/PGL, alongside SDHB, S100, Ki-67 proliferation index, and the expression of MAML3 and MCM6 in predicting metastatic disease.
The specimens of 71 patients who were diagnosed with PCC/PGL and underwent total excision between 2010 and 2021 were re-examined. Demographic, clinical, and histopathological data, as well as immunohistochemical results for Ki-67, S100, SDHB, MCM6, and MAML3, were recorded.
While distant organ metastasis was observed in 3.4% (n = 1/29) of PCC and 21.2% (n = 7/33) of head and neck PGL, this rate was found to be significantly higher at 66.7% (n = 6/9) in abdominal PGL (p < 0.001). No MAML3 overexpression was observed in any of the cases. Distant organ metastasis was more frequently detected in cases with MCM6 overexpression.
Although there is still no definitive feature that predicts metastasis, in line with the literature, extra-adrenal localization, vascular invasion, capsular invasion, nuclear pleomorphism, hyperchromasia, and confluent necrosis were found to be associated with distant organ metastasis in our study. Additionally, in the multivariate analysis, larger tumor size (> 5.1 cm), the presence of > 3/10 HPF mitosis, and SDHB loss were associated with lower metastasis-free survival. While no conclusions could be drawn regarding MAML3, the prognostic value of MCM6 appears promising.
目前尚无明确的预后标志物能够准确预测嗜铬细胞瘤/副神经节瘤(PCC/PGL)的恶性行为。虽然肾上腺起源的PCC/PGL仅有10% - 15%会发生转移,但肾上腺外定位的PCC/PGL转移率可高达50%。本研究旨在探讨已知的组织病理学特征以及SDHB、S100、Ki-67增殖指数、MAML3和MCM6的表达在预测PCC/PGL转移性疾病方面的潜在预测作用。
对2010年至2021年间诊断为PCC/PGL并接受根治性切除的71例患者的标本进行重新检查。记录人口统计学、临床和组织病理学数据,以及Ki-67、S100、SDHB、MCM6和MAML3的免疫组化结果。
PCC中3.4%(n = 1/29)、头颈部PGL中21.2%(n = 7/33)出现远处器官转移,而腹部PGL中这一比例显著更高,为66.7%(n = 6/9)(p < 0.001)。所有病例均未观察到MAML3过表达。MCM6过表达的病例更常检测到远处器官转移。
尽管仍没有预测转移的明确特征,但与文献一致,在我们的研究中发现肾上腺外定位、血管侵犯、包膜侵犯、核多形性、核深染和融合性坏死与远处器官转移相关。此外,在多变量分析中,肿瘤较大(> 5.1 cm)、每10个高倍视野有> 3个有丝分裂象以及SDHB缺失与无转移生存期较低相关。虽然关于MAML3无法得出结论,但MCM6的预后价值似乎很有前景。